MAIA Biotechnology, Inc. (MAIA) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Chicago, IL, United States. El CEO actual es Vlad Vitoc.
MAIA tiene fecha de IPO 2022-07-28, 13 empleados a tiempo completo, cotiza en el NYSE, una capitalización de mercado de $54.9M.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
